Galin, Shapiro Explore Process for Requesting Experimental Drugs in Law360

January 09, 2017

O’Melveny partner Ross Galin and associate Aaron Shapiro authored an article for the January 9, 2017, issue of Law360. The article, “Easing the Process for Requesting Experimental Drugs,” examines a lesser-reported provision of the 21st Century Cures Act that requires pharmaceutical companies to develop publicly available policies on how they evaluate patient requests for experimental drugs. 

The authors write that “this brief provision, tucked away in the middle of the law, enhances the ability of seriously ill patients to seek experimental drugs in a fair and transparent way.”

Based in New York, Galin represents corporations and individual clients in civil, regulatory, and criminal matters. Also based in New York, Shapiro is a litigation associate.